Search Results for: M Pharmaceutical Enters Into Exclusive
Articles
AVEO Enters Agreement With Ophthotech for Ocular Diseases November 18, 2014
AVEO Oncology recently announced it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it...InnoCore Enters Exclusive License Agreement With Allergan October 25, 2013
InnoCore Pharmaceuticals recently announced it has signed an exclusive license and collaboration agreement with Allergan, Inc. Under the agreement, the...EXECUTIVE INTERVIEW - West Pharmaceutical Services: Celebrating 90 Years of Healthcare Innovation July 10, 2013
Drug Development Executive: Donald E. Morel, Jr., PhD, Chairman and CEO, West, discusses how the company works closely with pharmaceutical and biotechnology companies to deliver life-changing therapies safely and effectively to patients.
Halozyme Therapeutics Enters Lucrative Agreement With Pfizer January 3, 2013
 Halozyme Therapeutics, Inc. recently announced it has entered into a worldwide collaboration and license agreement with Pfizer Inc. for...Teva Enters $376-Million Deal for Xenon's Pain Drug December 10, 2012
Teva Pharmaceutical Industries Ltd and Xenon Pharmaceuticals Inc. recently announced they have entered into a collaborative development and exclusive worldwide...Caisson Biotech Enters Potential $100 Million Agreement May 6, 2012
Caisson Biotech, L.L.C. recently announced it has entered into a development and license agreement with Novo Nordisk A/S. The agreement...Fortress Biotech & Cyprium Therapeutics Announce $4.1-Million Grant From NINDS to Further Develop Gene Therapy for Menkes Disease March 4, 2024
Cyprium Therapeutics, Inc. recently announced the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...2023 Analytical Testing eBook – Analytical Testing Evolves With the Pharma Industry August 14, 2023
In this fourth annual Analytical Testing e-book, learn more about Alcami, Stevanati Group, and West and their current contributions and offerings in the outsourcing analytical testing market, as it continues to be a time and money saver for bio/pharma companies.
2022 Analytical Testing eBook – Service Providers Offer Innovation August 23, 2022
Learn more about the technologies from Alcami, Associates of Cape Cod, Stevanato Group, and West in this exclusive 2022 Drug Development & Delivery Analytical Testing e-book.
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients With Advanced Solid Tumors May 10, 2022
Immatics N.V. recently announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER) IMA401 for patients with recurrent and/or refractory….
Genovac Acquires the Carterra LSA Instrument to Enable State-of-the-Art Antibody Screening & Characterization Services April 20, 2022
Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research...SPECIAL FEATURE - Excipients: Exciting Expansion & Innovation April 4, 2022
Contributor Cindy H. Dubin speaks with several companies and presents a unique look at how excipients are being used to support current and future innovative active pharmaceutical ingredients.
Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease December 7, 2021
Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….
SYRINGE PLUNGER - Exploring How the Functional Properties of the PremiumCoat® 1-3-mL Plunger Facilitate its Implementation on Filling Lines & Enable the Delivery of Sensitive Vaccines & Biotech Drugs October 4, 2021
Sebastien Cordier, Laure-Hélène Guillemot, PhD, and Audrey Chardonnet explain how the PremiumCoat 1-3-mL syringe plunger combines a pure Bromobutyl formulation with a market-proven ETFE film that acts as a barrier to limit the transfer of rubber leachables into the drug product.
Lykan Bioscience & Vineti Announce Partnership to Advance Cell-Based Therapies From Clinical to Commercialization August 17, 2021
Lykan Bioscience and Vineti recently announced a partnership to unite Lykan’s purpose-built cell therapy manufacturing capabilities and Vineti’s industry-leading….
OPEN INNOVATION PLATFORM - Incentivizing Drug Delivery Research Using an Open Sharing Platform March 29, 2021
Keith R. Horspool, PhD, Shirlynn Chen, PhD, and Markus Koester, PhD, discuss an open innovation platform to stimulate scientific understanding, and development of potential new technologies, for delivery of compounds with challenging solubility by offering a set of more contemporary poorly soluble drugs free-of-charge for independent research activities.
SPECIAL FEATURE - Injection Devices: Will COVID-19 Deliver Growth to the Market? September 1, 2020
Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
EXECUTIVE INTERVIEW - Tedor Pharma, Inc.: A Strategy Shift to Serve Both Generic & Branded Companies March 31, 2020
Doug Drysdale, President & CEO of Tedor Pharma, Inc., discusses the FLEXITAB technology, his strategy for managing a shift in business model, and how Tedor is addressing the needs of small- and medium-size companies developing innovative and repurposed small molecules for unmet medical needs.
2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal June 26, 2019
This e-Book highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.
REGENERATIVE MEDICINE - Cell Therapy - The Quest for Finding the Cure November 12, 2018
Aarti Chitale, MBA, believes as the therapeutic landscape evolves and transitions toward personalized and value-based care, regenerative medicine will play an increasingly important role, and moreover, the success of these therapies offers promising opportunities for previously untreated diseases areas.
